Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29593538 | 1.00 | PDCD1 (0.49) | PDCD1CD274 | |
| Potassium Ion SCHEMBL29831283 | 0.97 | PDCD1 (0.46) | PDCD1CD274 | |
| SCHEMBL30661738 | 0.95 | PDCD1 (0.43) | PDCD1CD274 | |
| SCHEMBL20293099 | 0.92 | PDCD1 (0.47) | PDCD1CD274 | |
| SCHEMBL29496802 | 0.92 | PDCD1 (0.47) | PDCD1CD274 | |
| SCHEMBL30684019 | 0.91 | USP30 (0.44) | PDCD1CD274 | |
| SCHEMBL23244398 | 0.89 | PDCD1 (0.53) | PDCD1CD274 | |
| SCHEMBL30033637 | 0.89 | PDCD1 (0.50) | PDCD1CD274 | |
| SCHEMBL20294247 | 0.86 | PDCD1 (0.65) | PDCD1CD274 | |
| SCHEMBL29933268 | 0.86 | PDCD1 (0.65) | PDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552811-B2 | Immunosuppressant, and preparation method therefor and use thereof | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2026-02-17 | — | — | US | disclosed |
| US-20260035388-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORP (US) | 2026-02-05 | — | — | US | disclosed |
| US-12473282-B2 | Biphenyl fluorine double bond derivative, preparation method therefor, and pharmaceutical application thereof | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2025-11-18 | — | — | US | disclosed |
| US-12466822-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250325660-A1 | IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE | INCYTE CORP (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250084104-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2025-03-13 | — | — | US | disclosed |
| EP-4520328-A2 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Corporation (US) | 2025-03-12 | — | — | EP | disclosed |
| US-12247038-B2 | Pyrido[3,2-d]pyrimidine compounds as immunomodulators | INCYTE CORPORATION (US) | 2025-03-11 | — | — | US | disclosed |
| US-12187743-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2025-01-07 | — | — | US | disclosed |
| EP-4219492-B1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORP (US) | 2024-11-27 | — | — | EP | disclosed |
| EP-3558990-A1 | TETRAHYDRO IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS PD-L1 INTERNALIZATION INDUCERS | Incyte Corporation (US) | 2019-10-30 | — | — | EP | disclosed |
| WO-2018119224-A1 | TETRAHYDRO IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS PD-L1 INTERNALIZATION INDUCERS | INCYTE CORPORATION (US) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018119224-A1 | TETRAHYDRO IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS PD-L1 INTERNALIZATION INDUCERS | INCYTE CORPORATION (US) | 2018-06-28 | — | — | WO | disclosed |
| US-20180177870-A1 | IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE | INCYTE CORPORATION | 2018-06-28 | — | — | US | disclosed |
| WO-2018119286-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2018-06-28 | — | — | WO | disclosed |
| US-20180177870-A1 | IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE | INCYTE CORPORATION | 2018-06-28 | — | — | US | disclosed |
| WO-2018119286-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2018-06-28 | — | — | WO | disclosed |
| US-20180179202-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-06-28 | — | — | US | disclosed |
| US-20180179202-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-06-28 | — | — | US | disclosed |
| US-20180179202-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179202-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | PDCD1 157/4885CD274 88/4885 |
| US-20250084104-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | PDCD1 157/4885CD274 88/4885 |
| US-12552811-B2 | Immunosuppressant, and preparation method therefor and use thereof | CD274, PDCD1, PDCD1LG2 | PDCD1 2/4885CD274 1/4885 |
| US-12247038-B2 | Pyrido[3,2-d]pyrimidine compounds as immunomodulators | PDCD1, CD274, PDCD1LG2 | PDCD1 1/4885CD274 2/4885 |
| US-20250325660-A1 | IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE | CD274, PDCD1LG2, PDCD1 | PDCD1 3/4885CD274 1/4885 |
| US-12466822-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | PDCD1 157/4885CD274 88/4885 |
| US-20260035388-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | IL2, IL4, NFATC1 | PDCD1 167/4885CD274 73/4885 |
| US-12473282-B2 | Biphenyl fluorine double bond derivative, preparation method therefor, and pharmaceutical application thereof | PDCD1, CD274, PDCD1LG2 | PDCD1 1/4885CD274 2/4885 |
| US-12187743-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | PDCD1 157/4885CD274 88/4885 |
| US-20180177870-A1 | IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE | CD274, PDCD1LG2, PDCD1 | PDCD1 3/4885CD274 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.